Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, Ro-associated Y4 pseudogene 17 (RNY4P17) is a human non-coding RNA gene classified as a processed pseudogene of the RNY4 locus, typically found annotated in genomic databases but lacking current evidence of protein-coding capacity or direct biological function. While the parent RNY4 gene is implicated in RNA stability, chromosomal DNA replication, and potential roles as a biomarker in cancers such as anaplastic large cell lymphoma, RNY4P17 specifically is not described as functionally relevant in any molecular, cellular, or pathological context in the literature reviewed[3][4]. Pseudogenes such as RNY4P17 can sometimes regulate gene expression at the RNA level—acting as competing endogenous RNAs (ceRNAs), antisense transcripts, or decoys for RNA binding proteins—but there are no published data indicating such functions for RNY4P17[4]. Unlike the bona fide RNY4 gene, RNY4P17 has not been reported as a biomarker, therapeutic target, or gene of disease relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, Ro-associated Y4 pseudogene 17 (RNY4P17).